B

iotech is having a banner year on Wall Street, with 33 IPOs to date and a median return rivaling that of the industry’s last boom. Whether it can last is anyone’s guess, and one ambitious startup is lining up to test just how much faith the public markets are willing to put into young, risky drug developers.

Rubius Therapeutics, founded in 2013, has no drugs in clinical trials but expects to raise $200 million and command a $1.8 billion valuation. If it succeeds, it will mark the year’s largest biotech IPO by a factor of two, outpacing companies whose products have already been tested in humans.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy